2024 ASCO Annual Meeting

Meet the Veristat team at ASCO,  May 31st to June 4th in Chicago  

The Science-First CRO™ and Consultancy Ready to Advance Your Revolutionary Therapy's Development, Approval, and Commercialization.  

If you are transitioning your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or are looking to recruit patients quickly to get your early phase trials running, or just need medical writing,  biostatistical,or pharmacovigilance support  for your programs – Veristat can help. 

For 30 years, Veristat has helped pharmaceutical and biotech companies accelerate their clinical trials and commercialize their therapies by delivering Science-First solutions across the development lifecycle.  

Oncology/Hematology Experience in the Past 5 Years

• +400 Clinical Trials & Consulting Projects
•  +30 Marketing Applications (NDAs, BLAs, MAAs) Prepared 
•  90% of global operations team members have oncology/hematology experience

We provide impactful solutions on a full-service or functional service basis, integrating strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel therapies.  
Our expertise encompasses traditional cancer treatments, devices/diagnostics, and specialized therapies, including vaccines, gene and cell therapies, and immunotherapies.
Don't miss this opportunity to connect with us at the Conference and learn more about how Veristat is advancing the development of new oncology therapies.

The Science-First CRO.™

Schedule A Meeting

Veristat team members, AJ Mills, Vice  President, Global Commercial, and Gabriela Rosu, Senior Director, Global Medical Affairs, will be at the venue, ready to listen to your needs and share Veristat’s expertise. Discover what makes Veristat a distinguished name in the clinical research industry. 

Arrange a meeting by completing the form on the right side of this page.  

Conference Details

Website: ASCO 2024